Headquartered in 79 New Oxford Street, London Fiscal year ends December NYSE: GSK gsk.com
GSK plc is a global biopharma company that develops, manufactures and sells prescription medicines and vaccines. Sales are reported in three product groups. Specialty Medicines covers HIV through its majority-owned ViiV Healthcare subsidiary (78.3% economic interest, with Shionogi holding 21.7%), including Dovato, Cabenuva, Apretude, Tivicay, Triumeq and Juluca. It also covers Respiratory, Immunology & Inflammation (Nucala, Benlysta, Exdensur) and Oncology (Jemperli, Ojjaara/Omjjara, Zejula, Blenrep and the newly launched Jideytro). Vaccines include Shingrix, the Bexsero, Menveo and Penmenvy meningitis vaccines, the Arexvy RSV vaccine, Fluarix/FluLaval, Boostrix and Infanrix. General Medicines comprises inhaled respiratory products such as Trelegy, Relvar/Breo, Anoro, Ventolin and Seretide/Advair, plus the antibiotic Blujepa. The US is its largest market, followed by Europe and International regions; it also earns royalty income, notably on Kesimpta. In 2026 GSK expanded its pipeline through acquisitions of Nuvalent (lung cancer kinase inhibitors), RAPT Therapeutics (ozureprubart) and 35Pharma (HS235 for pulmonary hypertension). It also launched Hibsago for chronic hepatitis B and began a three-year 'Accelerate Growth' restructuring to redirect resources to R&D. Late-stage programmes include ADCs Ris-Rez and Mo-Rez, efimosfermin for MASH, felcorekibart (anti-TSLP) and mRNA flu vaccines. Ahead of dolutegravir's 2028-2030 loss of exclusivity, GSK targets more than £40 billion in 2031 sales. Updated
One-off charges, led by £328 million of Accelerate Growth restructuring, pushed adjusted earnings below expectations while revenue beat estimates. Specialty Medicines grew 15% and management reaffirmed full-year guidance, so the operating story is intact.
GSK (NYSE:GSK | GSK Price Prediction) reports third-quarter results on October 28. A $2.2 billion Zantac settlement hits the books this quarter and a failed cough program is still fresh, so this…
Rich Duprey Cerebras stock cratered to a post-IPO low while rivals like NVIDIA and AMD surged, yet one of the world's largest banks just doubled down with a price target that implies the market…
The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has…
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to…
GSK has handed investors a remarkable run. Over the past year, the stock climbed roughly 44% from $37.79 to $54.51. If you watched from the sidelines, the question now is painfully familiar:…
William Temple Of everything C3.ai (NYSE: AI) | AI Price Prediction has promised investors over the years, tonight’s revenue number is the one that actually has to deliver. Not the deal count, not the…
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Live Updates Nvidia Drives Stock Market Higher4:25pm ETStrong performance from Dow Jones Industrial Average component company Nvidia (Nasdaq: NVDA | UNH Price Prediction) helped to drive the index higher Tuesday. Nvidia stock…
Merck just rewarded its shareholders again with a dividend hike. This Dow Jones industrial stock has come with a quarterly dividend for almost two decades.
Stock splits are typically viewed as bullish indicators that a company sees more growth is on the horizon. Although nothing fundamental changes about the business, making the share price cheaper allows more…
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists like Ozempic, Wegovy,…
The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back as April, Goldman Sachs (NYSE:GS | GS Price Prediction) warned of the…
Investors have been on a roller coaster ride for the past four years and the stock market may be heading into another big loop higher. Federal Reserve chairman Jay Powell gave his…
GSK plc is a global biopharma company that develops, manufactures and sells prescription medicines and vaccines. Sales are reported in three product groups.
24/7 Wall St.'s 12-month price target for GSK is $62.80, rated Buy. The Wall Street consensus target is $60.51. GSK price prediction →
